Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer

Abstract

Staging examination including FDG-PET/CT and brain magnetic resonance imaging ordinarily can determine the clinical stage and resectability of primary lung cancer. False-positive findings in regional lymph nodes, possibly reflecting past infectious disease, are the most important remaining problem.

Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial

“…Contrary to previous studies with induction chemotherapy reported by our collaborative group, in which 122 patients with stage IIIA-N2 were recruited over a similar time interval, this trial was prematurely closed because of slow accrual, what may be due to several factors: (1) the highly selective inclusion criteria, initially requiring mediastinoscopy, a procedure that is not routinely recommended in France for these patients [36]; (2) the broader availability of PET-scan, which has reduced the eligibility of patients with locally advanced NSCLC for surgical resection [37];…”

Methods for Staging Non-small Cell Lung Cancer

“…Overdiagnosis of nodal metastases can result in missed opportunities for surgical cure. 75 Incorrect upstaging was found in 4.8% of patients in Maziak's 29 series (compared with 0.6% in conventionally staged patients). Incorrect upstaging was equally likely in the mediastinum and in distant sites.…”